| Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers C Rossi, J Gilhodes, M Maerevoet, C Herbaux, F Morschhauser, P Brice, ... American Journal of Hematology 93 (8), 1042-1049, 2018 | 90 | 2018 |
| Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous … A de Masson, M Beylot-Barry, JD Bouaziz, RP de Latour, F Aubin, ... haematologica 99 (3), 527, 2014 | 82 | 2014 |
| Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in … X Leleu, G Fouquet, B Hebraud, M Roussel, D Caillot, ML Chrétien, ... Leukemia 27 (11), 2242-2244, 2013 | 75 | 2013 |
| Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma S Garciaz, D Coso, F Peyrade, S Fürst, S Duran, B Chetaille, ... Hematological oncology 32 (4), 187-191, 2014 | 67 | 2014 |
| Bendamustine‐based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from LYmphoma Study Association … SP Chantepie, S Garciaz, E Tchernonog, F Peyrade, MV Larcher, M Diouf, ... American journal of hematology 93 (6), 729-735, 2018 | 43 | 2018 |
| Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity S Garciaz, D Coso, JM Schiano de Collela, F Broussais, AM Stoppa, ... Bone Marrow Transplantation 51 (2), 319-321, 2016 | 40 | 2016 |
| Regulation of the positive transcriptional effect of PLZF through a non-canonical EZH2 activity M Koubi, M Poplineau, J Vernerey, L N’Guyen, G Tiberi, S Garciaz, ... Nucleic acids research 46 (7), 3339-3350, 2018 | 31 | 2018 |
| Contiguous follicular lymphoma and follicular lymphoma in situ harboring N-glycosylated sites E Mamessier, C Drevet, F Broussais-Guillaumot, ML Mollichella, ... haematologica 100 (4), e155, 2015 | 25 | 2015 |
| Lenalidomide for the treatment of B-cell lymphoma S Garciaz, D Coso, JM Schiano de Colella, R Bouabdallah Expert Opinion on Investigational Drugs 25 (9), 1103-1116, 2016 | 22 | 2016 |
| Patients’ non-medical characteristics contribute to collective medical decision-making at multidisciplinary oncological team meetings L Restivo, T Apostolidis, AD Bouhnik, S Garciaz, T Aurran, ... PLoS One 11 (5), e0154969, 2016 | 21 | 2016 |
| Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a … T Hueso, T Gastinne, S Garciaz, E Tchernonog, C Delette, ... Bone Marrow Transplantation 55 (6), 1076-1084, 2020 | 20 | 2020 |
| Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available S Garciaz, L Castagna, R Bouabdallah, S Fürst, S Bramanti, D Coso, ... Bone marrow transplantation 50 (6), 865-867, 2015 | 19 | 2015 |
| Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights JE Martin, S Khalife-Hachem, T Grinda, M Kfoury, S Garciaz, F Pasquier, ... Annals of Oncology 32 (8), 1046-1048, 2021 | 18 | 2021 |
| Pharmacologic reduction of mitochondrial iron triggers a noncanonical BAX/BAK-dependent cell death S Garciaz, AA Guirguis, S Müller, FC Brown, YC Chan, A Motazedian, ... Cancer Discovery 12 (3), 774-791, 2022 | 17 | 2022 |
| Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients S Garciaz, MA Hospital, AS Alary, C Saillard, Y Hicheri, B Mohty, J Rey, ... Cancers 14 (8), 2025, 2022 | 15 | 2022 |
| Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a … S Garciaz, M Loschi, A De Masson, L Biard, M Mercier, C Tomowiak, ... Leukemia & Lymphoma, 2019 | 11 | 2019 |
| Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients R Crocchiolo, L Castagna, S Garciaz, S Fürst, J El Cheikh, B Sarina, ... Haematologica 100 (10), e423, 2015 | 11 | 2015 |
| Partial response at completion of bortezomib-thalidomide-dexamethasone (VTd) induction regimen upfront in multiple myeloma does not preclude response to VTd in consolidation G Fouquet, B Hebraud, S Garciaz, AM Stoppa, M Roussel, D Caillot, ... Journal of Cancer 5 (3), 248, 2014 | 11 | 2014 |
| Venetoclax in acute myeloid leukemia: molecular basis, evidences for preclinical and clinical efficacy and strategies to target resistance S Garciaz, C Saillard, Y Hicheri, MA Hospital, N Vey Cancers 13 (22), 5608, 2021 | 10 | 2021 |
| Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation S Garciaz, L N’guyen Dasi, P Finetti, C Chevalier, J Vernerey, ... Clinical epigenetics 11 (1), 1-14, 2019 | 10 | 2019 |
